Matrix Mediated Viral Gene Delivery: A Review

Abstract

Polymeric matrices inherently protect viral vectors from preexisting immune conditions, limit dissemination to off-target sites, and can sustain vector release. Advancing methodologies in development of particulate based vehicles have led to improved encapsulation of viral vectors. Polymeric delivery systems have contributed to increasing cellular transduction, responsive release mechanisms, cellular infiltration, and cellular signaling. Synthetic polymers are easily customizable, and are capable of balancing matrix retention with cellular infiltration. Natural polymers contain inherent biorecognizable motifs adding therapeutic efficacy to the incorporated viral vector. Recombinant polymers use highly conserved motifs to carefully engineer matrices, allowing for precise design including elements of vector retention and responsive release mechanisms. Composite polymer systems provide opportunities to create matrices with unique properties. Carefully designed matrices can control spatiotemporal release patterns that synergize with approaches in regenerative medicine and antitumor therapies.

PROTAC targeted protein degraders: the past is prologue

“…As ARV-110 and ARV-471 have demonstrated, PROTACs can be developed as oral therapeutics, but bioPROTACs and hybrid PROTACs are unlikely to be oral drugs owing to their peptide components. Indeed, bioPROTACs would most likely be delivered as mRNA or DNA constructs via a viral vector gene delivery system [204][205][206] or in a nanoparticle [207][208][209] . bioPROTACs and pepTACs.…”

Materials promoting viral gene delivery

“…Matrixmediated viral delivery was recently reviewed elsewhere. 256 The following sections mainly cover saccharides in hydrogel applications.…”

Translational Development of a Silk‐Elastinlike Protein Polymer Embolic for Transcatheter Arterial Embolization

“…SELPs utilize an aqueous, passive transition mechanism for stable emboli formation, and are compatible with bioactive agents such as gene or immunotherapies. This transition easily allows for encapsulation of therapeutics and subsequent matrix mediated release, which has been extensively explored with gene therapy agents, [13,14,17,[28][29][30][31] semisynthetic glycosaminoglycan ethers, [10][11][12] and small molecular weight drugs. [9,18] Doxorubicin and sorafenib have sustained release profiles of a week or more from SELP matrices in vitro.…”